ANA Investigates
The latest in neurology and neuroscience, each month from the ANA!
ANA members are offered the opportunity to claim AMA PRA Category 1 Credits™. Detailed information about CME is available on OnDEC.
Catch the latest episodes of ANA Investigates online or through your preferred podcast app. Subscribe on Apple or Spotify and be the first to hear new episodes as they’re released!
ANA Investigates host and executive producer:
Ifrah Zawar, MD, University of Virginia
Episode producers and planners are members of the ANA’s Education Innovation Committee.
Recent Episodes
ANA Investigates At a time when support for basic and translational science needs a strong voice and the burden of neurological disease is growing, the ANA is the champion of neurological research and the ally of all physicians and scientists who strive to make a difference through careers that combine discovery, education, and clinical care. From advances in stroke and dementia to movement disorders and epilepsy, the American Neurological Association has been at the forefront of research and practice since 1875 as the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system.
- ANA Investigates Pediatric Epilepsy Surgeries
by The American Neurological Association on July 14, 2026 at 11:00 amIn this episode, we'll discuss pediatric epilepsy surgery. Pediatric epilepsy surgery has undergone a remarkable evolution, moving from a treatment of last resort to a critical option for children with drug-resistant epilepsies. Yet major barriers remain, including delayed referrals, fear of brain surgery, and uncertainty around risks and benefits. At the same time, advances in imaging, genetics, and neuromodulation are shaping the utility of epilepsy surgery. For an update in pediatric epilepsy surgery, we spoke with Dr. Ahsan Moosa Naduvil Valappil, a pediatric epileptologist and an associate professor of neurology at the Cleveland Clinic. Dr. Moosa is internationally recognized for his work in pediatric epilepsy surgery and complex hemispheric epilepsy syndromes. Dr. Moosa and his colleagues at Cleveland Clinic have helped advance our understanding of how surgical interventions can improve outcomes for children with epilepsy. Dr. Moosa was interviewed by Dr. Howard Goodkin, the Shure Professor of Neurology and Pediatrics at the University of Virginia. Disclosures: None
- ANA investigates ALS Research and Healey ALS MyMatch
by The American Neurological Association on June 9, 2026 at 11:00 amIn this episode, we will focus on the latest in the research on ALS. ALS remains a devastating disease, but the field is now at an inflection point with a growing pipeline of precision therapies, trial-ready sites, and a new generation of clinician scientists - yet barriers persist. There is disease heterogeneity, limited trial access for patients, and rising development costs. For an update on ALS clinical trials and the Healey ALS MyMatch program, a centralized platform that matches participants to trials, we spoke with Dr. Suma Babu. Dr. Suma Babu is an associate professor of neurology at Harvard Medical School and co-director of the Neurological Clinical Research Institute at Mass General Brigham. She was interviewed by Dr. Ryan Jacobson, an associate professor of neurology at Rush University. Disclosure: This episode does not award CME.
- ANA investigates the Evolution of the ANA Podcast
by The American Neurological Association on May 12, 2026 at 10:52 amANA Investigates is the official podcast of the American Neurological Association, featuring conversations that highlight the latest discoveries, controversies, and trends in academic neurology. After the successful release of over 80 podcast episodes, In today's episode, we'll explore the creation and evolution of the ANA Investigates podcast since its launch in September 2019. We have the privilege of hosting four legends who were instrumental in bringing this podcast to life. First, Dr. Adeline Goss, Assistant Professor at Highland Hospital in Oakland, California, whose background as a radio host uniquely positioned her to serve as ANA investigates Executive Producer for six years. We are also joined by Dr. Megan Richie, Associate Professor at UCSF, and Dr. Romer Geocadin, Professor at Johns Hopkins—both of whom played central roles in shaping the podcast from its earliest days through its evolution. Finally, we're joined by Jennifer Hurley, Education and Accreditation Manager for the American Neurological Association, who has been integral to the editing, production, and sustained success of every single episode. Disclosures: This episode does not award CME credit.
- ANA Investigates Debates in Idiopathic Normal Pressure Hydrocephalus
by The American Neurological Association on April 21, 2026 at 1:10 pmThe diagnosis and management of idiopathic normal pressure hydrocephalus (NPH) is evolving. However, skepticism about this diagnosis persists among neurologists based upon lack of disease specific pathology, overlap with other neurodegenerative processes, and a lack of uniform diagnostic criteria. Also, prior reports of minimal or transient improvement after treatment with an invasive procedure and lack of high-quality studies has concerned some neurologists. We are joined by 2 experts in the field of movement disorders and CSF flow – Dr. Alberto Espay and Dr. Michael Williams – to discuss advances in our understanding of idiopathic NPH, the PENS trial, and evidence still needed to convince neurologists that NPH is clinical syndrome that warrants timely evaluation and treatment. Guest(s): Dr. Alberto Espay, Professor of Neurology at the University of Cincinnati; Dr. Michael Williams, Professor Neurology and Neurological Surgery at the University of Washington Interviewer: Dr. Kara Wyant, Clinical Associate Professor of Neurology at the University of Michigan Disclosures: Dr. Espay: Consultancies & Scientific Advisory Boards Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma. Dr. Williams: I am a paid consultant to Aesculap regarding devices to treat hydrocephalus Dr. Wyant: Biovie - consulting, (NEW 8/2025) ongoing, UCB Pharma - research support, ended 6/2025, PhotoPharmics - research support, ongoing
- ANA Investigates Adaptive DBS
by The American Neurological Association on February 24, 2026 at 2:56 pmLast year, the FDA approved adaptive deep brain stimulation for the treatment of people with Parkinson's disease. This is a major step forward in neurology. It allows personalized therapy by adjusting deep brain stimulation settings in real-time based on an individual's brain signals. Our guest on this episode is Dr. Helen Bronte-Stewart, the John E. Cahill Family Professor of Neurology and Director of the Human Motor Control and Neuromodulation Lab at Stanford University. Dr. Bronte-Stewart was interviewed by Dr. Karlo Lizarraga, Associate Professor of Neurology and Director of the Motor Physiology and Neuromodulation program at the University of Rochester. Disclosures: Dr. Bronte-Stewart disclosed equity in QDG Health. Dr. Lizarraga disclosed FHC: Consulting (Course Instructor), BlueRock: Research support.